Global Information
회사소개 | 문의 | 비교리스트

면역 체크포인트 억제제 시장 : 시장 기회 분석 및 향후 예측

Immune Checkpoint Inhibitors Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

리서치사 Coherent Market Insights
발행일 2019년 03월 상품 코드 817599
페이지 정보 영문
가격
US $ 4,500 ₩ 5,577,000 PPT Turned PDF (Single User License)
US $ 7,000 ₩ 8,675,000 PPT Turned PDF (Multi-user License)
US $ 10,000 ₩ 12,394,000 PPT Turned PDF (Enterprise User License)


면역 체크포인트 억제제 시장 : 시장 기회 분석 및 향후 예측 Immune Checkpoint Inhibitors Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026
발행일 : 2019년 03월 페이지 정보 : 영문

세계의 면역 체크포인트 억제제(면역 관문 억제제) 시장을 조사했으며, 시장 개요, 종류·용도·지역별 시장 동향, 시장 규모 추이와 예측, 시장 성장 촉진요인 및 저해요인, 시장 기회 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 조사 목적과 전제조건

  • 조사 목적
  • 전제조건
  • 약어

제2장 시장 개요

  • 보고서 설명
    • 시장 정의와 범위
  • 주요 요약
    • 시장 개요 : 약제 클래스별
    • 시장 개요 : 용도별
    • 시장 개요 : 지역별
  • Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

  • 시장 역학
    • 성장 촉진요인
    • 성장 저해요인
    • 시장 기회
  • 영향 분석
  • 역학
  • 제휴와 파트너십
  • 주요 FDA 승인과 제품 발매 시나리오
  • 파이프라인 분석
  • 규제 시나리오
  • 환급 시나리오
  • PEST 분석
  • Five Forces 분석

제4장 면역 체크포인트 억제제 시장 : 약제 클래스별

  • 서론
  • PD-1 억제제
  • PD-L1 억제제
  • CTL-4 억제제
  • IDO 억제제
  • 림프구 활성화 유전자 3 억제제

제5장 면역 체크포인트 억제제 시장 : 용도별

  • 서론
  • 폐암
  • 두경부암
  • 피부암(흑색종, 메르켈세포암)
  • 혈액암(림프종)
  • 방광암(요로상피암)
  • 신장/신장암
  • 대장암
  • 유방암
  • 기타

제6장 면역 체크포인트 억제제 시장 : 유통채널별

  • 서론
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제7장 면역 체크포인트 억제제 시장 : 지역별

  • 서론
  • 북미
  • 유럽
  • 아시아태평양
  • 중남미
  • 중동
  • 아프리카

제8장 경쟁 환경

  • 히트 맵 분석
  • 기업 개요
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • AstraZeneca Plc
    • Novartis International AG
    • ImmunOs Therapeutics AG
    • Immutep Ltd.
    • NewLink Genetics Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.

제9장 섹션

  • 참고 문헌
  • 조사 방법
  • Coherent Market Insights에 대해
LSH 19.04.23

Immune checkpoint inhibitor products come under biologic therapeutic products. Biologic manufacturers require similar kind of approvals such as drugs from the U.S. Food & Drug Administration prior to bringing the product into market. However, unlike drugs, biologics require Biologics License Applications (BLA) to be filed with the Center for Biologics Evaluation and Research (CBER). Initiatives undertaken by the governments include funding is expected to drive growth of the immune checkpoint inhibitors market. For instance, in 2017, National Institutes of Health partnered with 11 leading biopharmaceutical companies such as AbbVie and Amgen, Inc. to accelerate development of new immunotherapies.

Market Dynamics

Global Immune checkpoint inhibitors market is driven by factors such as increasing prevalence of cancer, active research and development by leading manufacturers through collaborations and individual research, and robust pipeline of immune checkpoint inhibitor combination therapies. According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, around 8.8 million deaths, and around 32.6 million of people suffering from cancer worldwide. There are many immune checkpoint inhibitors combination therapies in the pipeline. Immune checkpoint inhibitors has proven clinical profile and increasing approvals to include more indication for existing drugs such as Nivolumab, which in turn is expected to boost global immune checkpoint inhibitors market growth over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of Global Immune Checkpoint Inhibitors Market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2018-2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the Global Immune Checkpoint Inhibitors Market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
  • Key companies covered as a part of this study include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, By Technology up-gradation, market expansion, and marketing tactics
  • The global immune checkpoint inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the Global Immune Checkpoint Inhibitors Market

Detailed Segmentation:

  • Global Immune Checkpoint Inhibitors Market, By Drug Class:
    • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
    • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
    • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
    • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    • Lymphocyte-Activation Gene 3 Inhibitors
  • Global Immune Checkpoint Inhibitors Market, By Cancer Type:
    • Lung Cancer
    • Head & Neck Cancer
    • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    • Blood Cancer (Lymphoma)
    • Bladder Cancer (Urothelial Carcinoma)
    • Renal/Kidney Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Others
  • Global Immune Checkpoint Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Immune Checkpoint Inhibitors Market, By Geography:
    • North America
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Europe
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Russia
      • Spain
      • Rest of Europe
    • Asia Pacific
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of APAC
    • Latin America
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of LATAM
    • Middle East
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • North Africa
      • Central Africa
      • South Africa
  • Company Profiles
    • Bristol-Myers Squibb Company*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • AstraZeneca Plc
    • Novartis International AG
    • ImmunOs Therapeutics AG
    • Immutep Ltd.
    • NewLink Genetics Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Application
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Epidemiology
  • Collaborations & Partnerships
  • Major FDA Approvals & Product Launch Scenario
  • Pipeline Analysis
  • Regulatory Scenario
  • Reimbursement Scenario
  • PEST Analysis
  • Porter's Five Forces Analysis

4. Global Immune Checkpoint Inhibitors Market, By Drug Class, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Programmed Death Receptor-1 (PD-1) Inhibitors
    • Pembrolizumab (Keytruda)
    • Nivolumab (Opdivo)
    • Cemiplimab (Libtayo)
    • Others
  • Programmed Death-Ligand 1 (PD-L1) Inhibitors
    • Atezolizumab (Tecentriq)
    • Avelumab (Bavencio)
    • Durvalumab (Imfinzi)
  • CTL-4 Checkpoint Inhibitor
    • Ipilimumab (Yervoy)
  • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
  • Lymphocyte-Activation Gene 3 Inhibitors

5. Global Immune Checkpoint Inhibitors Market, By Application, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Head & Neck Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Blood Cancer (Lymphoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Bladder Cancer (Urothelial Carcinoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Renal/Kidney Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)

6. Global Immune Checkpoint Inhibitors Market, By Distribution Channel, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)

7. Global Immune Checkpoint Inhibitors Market, By Regions, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2026
  • North America
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Bristol-Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • F. Hoffmann-La Roche AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • ImmunOs Therapeutics AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Immutep Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • NewLink Genetics Corporation
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Ono Pharmaceutical Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top
전화 문의
F A Q